{
  "id": 16890074,
  "title": "Oppenheimer reiterates Outperform on UroGen Pharma stock at $60",
  "url": "https://urgent.news/2026/10/28/oppenheimer-reiterates-outperform-on-urogen-pharma-stock-at-60",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T11:20:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-reiterates-outperform-on-urogen-pharma-stock-at-60-93CH-4978595"
  },
  "original_language": "en",
  "account": "Oppenheimer maintains an Outperform rating and sets a $60.00 price target on UroGen Pharma's (NASDAQ:URGN) stock following meetings with the company. Analysts range their price targets from $48 to $75, and InvestingPro indicates UroGen is currently undervalued compared to its Fair Value estimate. UroGen recently showcased its commercial potential for Zusduri in Denver and Los Angeles. The company anticipates steady quarterly growth through 2026 and sees potential for an inflection point next year from direct-to-consumer marketing. UroGen's revenue skyrocketed by over 100% in the past 12 months, and analysts predict continued sales growth this year, with five analysts revising earnings upwards. Despite a small portion of targeted physicians using the product, Oppenheimer remains confident in UroGen's 2030 peak sales forecast of $1.2 billion. UroGen's gross profit margin of ~91% demonstrates strong commercial viability. The company announced impressive Q2 2026 results, with revenue exceeding $72.5 million, surpassing estimates of $62.82 million. This growth is primarily attributed to Zusduri's commercial rollout, which generated $50.4 million in product revenue—a 73% increase from the previous quarter. UroGen's full-year guidance remains between $97 million and $101 million. Guggenheim upgraded its price target to $58 from $42, maintaining a Buy rating, while H.C. Wainwright reiterated a Buy rating and set a price target of $75, emphasizing the FDA's acceptance of UroGen's New Drug Application for UGN-103, a mitomycin formulation for intravesical solution. Jefferies also maintained a Buy rating, setting a price target of $56. These developments highlight UroGen Pharma's positive momentum in the pharmaceutical industry.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}